€127.00
Your prediction
Ascendis Ph.sp.adr 1 Dk 1 Stock
Pros and Cons of Ascendis Ph.sp.adr 1 Dk 1 in the next few years
Pros
Cons
Performance of Ascendis Ph.sp.adr 1 Dk 1 vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ascendis Ph.sp.adr 1 Dk 1 | -0.780% | -6.569% | - | - | - | - | - |
| Novocure Ltd | 3.070% | 0.751% | -6.366% | -79.489% | -20.140% | -93.120% | - |
| Sage Therapeutics Inc. | -0.350% | 7.594% | -26.705% | -70.648% | -36.600% | -79.905% | - |
| Iovance Biotherapeutics Inc. | -1.440% | -2.226% | -20.178% | 108.608% | 37.807% | -58.359% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Ascendis Pharma, a prominent player in the biotechnology and medical research industry, exhibits a rather intriguing financial performance. From a bird's-eye view, the company has continually invested large sums into research and development which indicates its commitment to innovation and progress. Furthermore, the company maintains a considerable cash reserve, that in turn, showcases its potential to sustain itself in the long run. However, it is also essential to examine the company's financials in detail to take note of the pros and cons before making any definitive conclusions.
Strong Cash Position: Ascendis Pharma's cash position has remained fairly stable over the past few years, with EUR 444.77 million as of 2022-12-31. By maintaining a robust cash reserve, the company is well-equipped to finance its operations, fund research and development, and seize business opportunities.
Focus on Research and Development: Ascendis Pharma has significantly and consistently invested in research and development. In 2022, the company allocated EUR 379.62 million to this domain. By prioritizing innovation, Ascendis Pharma is likely to stay at the forefront of the biotechnology and medical research industry.
